253 related articles for article (PubMed ID: 28435071)
1. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells.
Sun Q; Liang Y; Zhang T; Wang K; Yang X
Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071
[TBL] [Abstract][Full Text] [Related]
2. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
3. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
4. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
[TBL] [Abstract][Full Text] [Related]
5. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
Zhang J; Li G; Li Z; Yu X; Zheng Y; Jin K; Wang H; Gong Y; Sun X; Teng X; Cao J; Teng L
Steroids; 2012 May; 77(6):666-73. PubMed ID: 22402113
[TBL] [Abstract][Full Text] [Related]
7. A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells.
Lin SL; Yan LY; Liang XW; Wang ZB; Wang ZY; Qiao J; Schatten H; Sun QY
Reprod Biol Endocrinol; 2009 Sep; 7():102. PubMed ID: 19775474
[TBL] [Abstract][Full Text] [Related]
8. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
9. Biphasic ER-α36-mediated estrogen signaling regulates growth of gastric cancer cells.
Wang X; Huang X; Fu Z; Zou F; Li Y; Wang Z; Liu L
Int J Oncol; 2014 Dec; 45(6):2325-30. PubMed ID: 25231129
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
11. The location of estrogen receptor variant ER-α36 is associated with the invasion of glioblastoma.
Li H; Ge N; Guan X; Han C; Li Y; Shen L; Chen M; Zhang B; Qu C; Zou W
Steroids; 2023 Jun; 194():109224. PubMed ID: 36924815
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
14. The ER-α36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells.
You H; Meng K; Wang ZY
Steroids; 2018 Jun; 134():78-87. PubMed ID: 29481815
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor α36 mediates a bone-sparing effect of 17β-estrodiol in postmenopausal women.
Xie H; Sun M; Liao XB; Yuan LQ; Sheng ZF; Meng JC; Wang D; Yu ZY; Zhang LY; Zhou HD; Luo XH; Li H; Wu XP; Wei QY; Tang SY; Wang ZY; Liao EY
J Bone Miner Res; 2011 Jan; 26(1):156-68. PubMed ID: 20578216
[TBL] [Abstract][Full Text] [Related]
16. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
[TBL] [Abstract][Full Text] [Related]
17. Chaperone gp96 mediates ER-α36 cell membrane expression.
Hou J; Deng M; Li X; Liu W; Chu X; Wang J; Chen F; Meng S
Oncotarget; 2015 Oct; 6(31):31857-67. PubMed ID: 26396174
[TBL] [Abstract][Full Text] [Related]
18. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling.
Kang L; Zhang X; Xie Y; Tu Y; Wang D; Liu Z; Wang ZY
Mol Endocrinol; 2010 Apr; 24(4):709-21. PubMed ID: 20197310
[TBL] [Abstract][Full Text] [Related]
19. ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcinogenesis in endometrial cancer.
Tu BB; Lin SL; Yan LY; Wang ZY; Sun QY; Qiao J
Am J Obstet Gynecol; 2011 Sep; 205(3):227.e1-6. PubMed ID: 21684519
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.
Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W
Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
